An immunohistochemical analysis of cyclin D1, p53. and p21waf1/cip1 proteins in tumors originating from the follicular epithelium of the thyroid gland

被引:22
作者
Goto, A
Sakamoto, A
Machinami, R
机构
[1] Kyorin Univ, Sch Med, Dept Pathol, Tokyo 1818611, Japan
[2] Kawakita Gen Hosp, Dept Pathol, Tokyo, Japan
关键词
thyroid tumor; immunohistochemistry; cyclin D1; p53; p21(waf1/cip1);
D O I
10.1078/0344-0338-00037
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This study aimed at clarifying the factors closely related to the tumor progression of thyroid neoplasms. We examined the immunoreactivity of cyclin D1, p53, and p21(waf1/cip1) proteins in 179 thyroid tumors originating from the follicular epithelium using an immunohistochemical technique. Cyclin D1 positivity was frequent in well-differentiated thyroid carcinomas (39/122 cases), but it was rarely seen in follicular adenomas (1/33 cases), (p < 0.05). Positivity for p53 was more frequent in poorly differentiated carcinomas (7/19 cases) and undifferentiated carcinomas (4/5 cases) than in well-differentiated carcinomas (14/122 cases) (p < 0,05, respectively). P21(waf1/cip1) positivity was more frequent in well-differentiated thyroid carcinomas (43/122 cases) than in follicular adenomas (4/33 cases) (p < 0.05). Regarding the relationships of these proteins, co-positivity for cyclin D1 and p53 was observed more often in poorly differentiated carcinomas (5/7 cases) than in well-differentiated carcinomas (7/39 cases) (p < 0.05). Most cases with cyclin D1 positivity did not show p21(waf1/cip1) expression in poorly differentiated carcinomas (6/7 cases). Three cases examined showed co-positivity of p53 and p21(waf1/cip1). Our results suggest that cyclin D1 is invoved in thyroid oncogenesis. Moreover, p53 might be closely related to the development of poorly differentiated carcinomas and undifferentiated carcinomas originating from well-differentiated carcinomas.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 32 条
[1]   CYCLIN D1 PROTEIN-ANALYSIS IN THE DIAGNOSIS OF MANTLE CELL LYMPHOMA [J].
DEBOER, CJ ;
SCHUURING, E ;
DREEF, E ;
PETERS, G ;
BARTEK, J ;
KLUIN, PM ;
VANKRIEKEN, JHJM .
BLOOD, 1995, 86 (07) :2715-2723
[2]   OVEREXPRESSION OF P53 AS A POSSIBLE PROGNOSTIC FACTOR IN HUMAN THYROID-CARCINOMA [J].
DOBASHI, Y ;
SAKAMOTO, A ;
SUGIMURA, H ;
MERNYEI, M ;
MORI, M ;
OYAMA, T ;
MACHINAMI, R .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (04) :375-381
[3]   STEPWISE PARTICIPATION OF P53 GENE MUTATION DURING DEDIFFERENTIATION OF HUMAN THYROID CARCINOMAS [J].
DOBASHI, Y ;
SUGIMURA, H ;
SAKAMOTO, A ;
MERNYEI, M ;
MORI, M ;
OYAMA, T ;
MACHINAMI, R .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1994, 3 (01) :9-14
[4]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[5]   p53 and translational control [J].
Ewen, ME ;
Miller, SJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1242 (03) :181-184
[6]  
GREENBLATT MS, 1994, CANCER RES, V54, P4855
[7]  
Hedinger CE, 1974, HISTOLOGICAL TYPING
[8]  
Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO
[9]  
2-5
[10]   Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues [J].
Ito, Y ;
Kobayashi, T ;
Takeda, T ;
Komoike, Y ;
Wakasugi, E ;
Tamaki, Y ;
Tsujimoto, M ;
Matsuura, N ;
Monden, M .
BRITISH JOURNAL OF CANCER, 1996, 74 (08) :1269-1274